Insights

Niche Neuro Gene Therapy Lysogene focuses on neurodegenerative lysosomal storage disorders in children, presenting a clear target for partnerships or collaborations with gene therapy platforms, contract research organizations, and pediatric neurology networks seeking specialized programs.

Clinical Experience Advantage With a decade of development experience from discovery to regulatory review, Lysogene offers potential partners access to seasoned translational expertise, favorable collaboration terms, and knowledge transfer opportunities to accelerate joint programs.

Recent Funding Fortitude Raised significant capital and maintains steady funding despite modest revenue, signaling financial backing to support co-development deals, milestone-driven partnerships, and potential out-licensing or in-licensing conversations.

Strategic Partnerships Existing collaboration with Sarepta Therapeutics indicates openness to strategic alliances; explore additional co-development, co-commercialization, or manufacturing partnerships to expand program reach and reduce time to clinic.

Growth Readiness Company size and focus on pediatric gene therapy suggest readiness for scaled out-licensing, milestone-based deals, and access to specialized CROs, manufacturing, and regulatory navigation expertise for late-stage endeavors.

Similar companies to LYSOGENE

LYSOGENE Tech Stack

LYSOGENE uses 8 technology products and services including RSS, WordPress, Mailchimp, and more. Explore LYSOGENE's tech stack below.

  • RSS
    Content Management System
  • Content Management System
  • Miscellaneous
  • OVHcloud
    Platform As A Service
  • Google Tag Manager
    Tag Management
  • Contact Form 7
    Web Platform Extensions

LYSOGENE's Email Address Formats

LYSOGENE uses at least 4 email formats:
LYSOGENE Email FormatsExamplePercentage
First.Last@lysogene.comJohn.Doe@lysogene.com
77%
FLast@lysogene.comJDoe@lysogene.com
12%
Last@lysogene.comDoe@lysogene.com
6%
FirstMLa@lysogene.comJohnMDo@lysogene.com
5%

Frequently Asked Questions

What is LYSOGENE's phone number?

Minus sign iconPlus sign icon
You can contact LYSOGENE's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is LYSOGENE's stock symbol?

Minus sign iconPlus sign icon
LYSOGENE is a publicly traded company; the company's stock symbol is LYS.PA.

What is LYSOGENE's official website and social media links?

Minus sign iconPlus sign icon
LYSOGENE's official website is lysogene.com and has social profiles on LinkedIn.

How much revenue does LYSOGENE generate?

Minus sign iconPlus sign icon
As of July 2026, LYSOGENE's annual revenue is estimated to be <$1M.

What is LYSOGENE's SIC code and NAICS code?

Minus sign iconPlus sign icon
LYSOGENE's SIC code is 8733 - Noncommercial Research Organizations and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does LYSOGENE have currently?

Minus sign iconPlus sign icon
As of July 2026, LYSOGENE has approximately 25 employees across 2 continents, including Europe and Asia. Key team members include Ceo: K. A., Chief Technical Officer: M. P. and International Clinical Project Manager: A. K. Explore LYSOGENE's employee directory with LeadIQ.

What industry does LYSOGENE belong to?

Minus sign iconPlus sign icon
LYSOGENE operates in the Biotechnology industry.

What technology does LYSOGENE use?

Minus sign iconPlus sign icon
LYSOGENE's tech stack includes RSS, WordPress, Mailchimp, Microsoft 365, DocuSign, OVHcloud, Google Tag Manager and Contact Form 7.

What is LYSOGENE's email format?

Minus sign iconPlus sign icon
LYSOGENE's email format typically follows the pattern of First.Last@lysogene.com. Find more LYSOGENE email formats with LeadIQ.

How much funding has LYSOGENE raised to date?

Minus sign iconPlus sign icon
As of July 2026, LYSOGENE has raised $30M in funding. The last funding round occurred on Dec 24, 2021 for $3.4M.

When was LYSOGENE founded?

Minus sign iconPlus sign icon
LYSOGENE was founded in 2009.
LYSOGENE logo

LYSOGENE

BiotechnologyÎle-de-France, France11-50 Employees

LYSOGENE is a biotechnology research company focused on gene therapy, with lead programs addressing neurodegenerative lysosomal storage disorders that affect children. It is based in Neuilly-sur-Seine, Île-de-France, France, and employs 11 to 50 people. Founded in 2009 by Karen Aiach, Lysogene has developed experience across discovery through clinical development, regulatory review, and related phases of gene therapy programs. The company has established a partnership with Sarepta Therapeutics and has attracted investment from top-tier investors. More information is available on its website at lysogene.com.

Section iconCompany Overview

Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
LYS.PA
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2009
Employees
11-50

Section iconFunding & Financials

  • $30M

    LYSOGENE has raised a total of $30M of funding over 3 rounds. Their latest funding round was raised on Dec 24, 2021 in the amount of $3.4M as a Post IPO Debt.

  • <$1M

    LYSOGENE's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.